---
title: "Zipalertinib (CLN-081): EGFR exon 20 insertion-mutated non-small-cell lung cancer"
description: "Formulary evidence on Zipalertinib (CLN-081, TAS6417) in EGFR exon 20 insertion-mutated non-small-cell lung cancer. Clinical evidence covers REZILIENT1, REZILIENT3, REZILIENT2, and REZILIENT4. 134 evidence topics quoted from 74 sources. Every quote links to the document it came from."
canonical: "https://www.evicenter.com/drugs/zipalertinib--egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer"
published: "2026-09-14T15:39:06-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Zipalertinib (CLN-081): EGFR exon 20 insertion-mutated non-small-cell lung cancer

<a id="executive-summary"></a>

## 1 Executive Summary

<a id="heading-1.1"></a>

### 1.1 Clinical Benefits of Zipalertinib

<a id="heading-1.1.1"></a>

#### 1.1.1 Burden of EGFR exon 20 insertion-mutated non-small-cell lung cancer

<a id="topic-1.1.1-1"></a>

##### Summary

In a genomic-profiling series of 14,483 NSCLC cases, 263 (1.8%) had EGFR exon 20 insertions, representing 12% of EGFR-mutated cases. These are case-series frequencies, not population incidence rates. A retrospective comparison reported median real-world overall survival of 16.2 months with exon 20 insertions versus 25.5 months with common EGFR mutations. A separate analysis projected that PCR-based assays would miss approximately 50% of variants identified by NGS.

Source: [Riess et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6764748/); [Bazhenova et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34818606/); [Viteri et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9892822/)

<a id="heading-1.1.2"></a>

#### 1.1.2 Zipalertinib Efficacy and Safety

<a id="topic-1.1.2-1"></a>

##### Summary

REZILIENT1 included 176 participants in its pivotal efficacy population and 244 in its safety population. Among 125 participants with prior platinum-based chemotherapy only, ORR was 40% and median DOR was 8.8 months. Two treatment-related deaths were reported in the safety population. In REZILIENT3, 279 participants were randomized. Median PFS was 14.5 months with Zipalertinib plus chemotherapy versus 8.5 months with chemotherapy, with a hazard ratio of 0.50. Grade ≥3 adverse events occurred in 87.1% versus 54.4%, respectively.

Source: [Cullinan Therapeutics ASCO oral presentation (2025)](https://cullinantherapeutics.com/wp-content/uploads/2025/09/CLN-081-ASCO-2025-Oral-Presentation.pdf); [Taiho Oncology REZILIENT1 Journal of Clinical Oncology publication announcement (2025)](https://www.taihooncology.com/us/news/taiho-oncology-and-cullinan-therapeutics-announce-pivotal-rezilient1-phase-12-data-published-in-the-journal-of-clinical-oncology/); [Taiho Pharmaceutical (2026)](https://www.taiho.co.jp/en/release/2026/20260914.html)

<a id="heading-1.1.3"></a>

#### 1.1.3 Budget Impact of Zipalertinib

No evidence found.

<a id="heading-1.1.4"></a>

#### 1.1.4 Conclusions

<a id="topic-1.1.4-1"></a>

##### Summary

Zipalertinib remains investigational. The NDA concerns treatment after platinum-based chemotherapy, with or without amivantamab; the stated FDA target action date is February 27, 2027. The first-line REZILIENT3 combination results address a different treatment setting. At its interim OS analysis, event maturity was 30% and the hazard ratio was 0.72 with a 95% CI of 0.42 to 1.23, so an OS benefit is not established by that analysis.

Source: [Taiho Oncology REZILIENT3 presidential symposium announcement (2026)](https://www.taihooncology.com/us/news/zipalertinib-plus-chemotherapy-first-line-phase-3-rezilient3-trial-data-selected-for-presidential-symposium-presentation-at-the-iaslc-2026-world-conference-on-lung-cancer/); [Taiho Oncology new drug application acceptance announcement (2026)](https://www.taihooncology.com/us/news/us-food-and-drug-administration-accepts-new-drug-application-for-zipalertinib-for-the-treatment-of-locally-advanced-or-metastatic-non-small-cell-lung-cancer-with-egfr-exon-20-insertion-mutations/); [Cullinan Therapeutics](https://cullinantherapeutics.com/science/pipeline/); [Taiho Pharmaceutical (2026)](https://www.taiho.co.jp/en/release/2026/20260914.html)

## Related pages
- [Zipalertinib (CLN-081) in EGFR exon 20 insertion-mutated non-small-cell lung cancer: Terms and abbreviations](https://www.evicenter.com/drugs/zipalertinib--egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/zipalertinib--egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer/terms-and-abbreviations.md)
- [Zipalertinib (CLN-081): EGFR exon 20 insertion-mutated non-small-cell lung cancer](https://www.evicenter.com/drugs/zipalertinib--egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/zipalertinib--egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer/executive-summary.md)
- [Zipalertinib (CLN-081) in EGFR exon 20 insertion-mutated non-small-cell lung cancer: Product information and disease description](https://www.evicenter.com/drugs/zipalertinib--egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/zipalertinib--egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer/product-information-and-disease-description.md)
- [Zipalertinib (CLN-081) in EGFR exon 20 insertion-mutated non-small-cell lung cancer: Clinical evidence](https://www.evicenter.com/drugs/zipalertinib--egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/zipalertinib--egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer/clinical-evidence.md)
- [Zipalertinib (CLN-081) in EGFR exon 20 insertion-mutated non-small-cell lung cancer: Economic information and modeling report](https://www.evicenter.com/drugs/zipalertinib--egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/zipalertinib--egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer/economics.md)
- [Zipalertinib (CLN-081) in EGFR exon 20 insertion-mutated non-small-cell lung cancer: References](https://www.evicenter.com/drugs/zipalertinib--egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer/references) · [Markdown](https://www.evicenter.com/drugs/zipalertinib--egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer/references.md)
- [Zipalertinib (CLN-081) in EGFR exon 20 insertion-mutated non-small-cell lung cancer: prevalence by geography](https://www.evicenter.com/drugs/zipalertinib--egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer/prevalence) · [Markdown](https://www.evicenter.com/drugs/zipalertinib--egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer/prevalence.md)
- [Zipalertinib (CLN-081) in EGFR exon 20 insertion-mutated non-small-cell lung cancer: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/zipalertinib--egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/zipalertinib--egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer/cost-effectiveness-analyses.md)
